Most scientific meetings include posters by scientists, which summarize their most recent experiments. The 3rd World Parkinson Congress is unique in that it features posters by advocates with Parkinson’s alongside those by scientists. PDF is proud to report that our team had 13 posters at the WPC! This included posters from seven PDF Research Advocates (one doubled up), three PDF staff members, and two PDF-funded researchers. Yesterday we were able to catch up with a few of them. Here’s a summary:
The 3rd World Parkinson Congress includes three days of sessions discussing the latest in Parkinson’s science and care. PDF’s reporters are listening in and reporting back to let you know what they have seen and heard. In particular, PDF Research Advocates Kim and Libbe Erickson of Stillwater, MN, were busy yesterday reporting on three sessions – covering treatments such as levodopa, the search for biomarkers and updates on deep brain stimulation. Here are their reports:
Excited. Filled with Anticipation. Overwhelmed, in a good way. And to think it all started close to four months ago, in June. That is when my husband John and I decided to attend the World Parkinson’s Congress 2013. Given the fact that it only happens once every three years, it’s the single largest worldwide gathering of all stakeholders in the Parkinson’s field, and we missed it the last go around — we weren’t going to let that happen again.
From Linda Morgan, M.B.A., R.Ph., member People with Parkinson’s Advisory Council I arrived early in Montreal for the 3rd World Parkinson Congress, which will officially start on Tuesday. I came in early to be part of an ‘historic’ dinner and meeting between researchers from the Parkinson Study Group (PSG) and those of us involved with Parkinson’s Advocates in Research (PAIR).
From James Beck, Ph.D., Vice President of Research Programs Using old drugs as new cures seems like a surefire winner. It may be. However, after attending a recent meeting outside London hosted by the Cure Parkinson’s Trust, a small yet impactful British charity, it is clear that this path is neither clear nor easy. A committee of experts at the meeting evaluated and prioritized dozens of existing compounds – many are drugs used to treat other diseases – based upon their potential to stop Parkinson’s disease.
From James Beck, Ph.D., Director of Research Programs This blog is part two in a series of three about the BigBrain. Several weeks ago saw the announcement of a description of a new and highly detailed atlas of the brain, called BigBrain. PDF wrote about how one person, making the decision to donate their brain, has made a significant contribution to science. Indeed, that is true. But what does this really mean for the future of neuroscience … and Parkinson’s research?